<p>Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens</p>
Fangwen Zhang(First Affiliated Hospital of Zhengzhou University), Mingzhi Zhang(Chinese Academy of Sciences), Xinhua Wang(Zhengzhou University), Lei Zhang(Hubei University of Medicine), Ling Li(First Affiliated Hospital of Zhengzhou University), Jingjing Wu(Beijing Tian Tan Hospital), Zhenchang Sun(First Affiliated Hospital of Zhengzhou University), Fei Kong(Shanghai Jiao Tong University), Liangliang Ren(First Affiliated Hospital of Zhengzhou University), Xiaorui Fu(First Affiliated Hospital of Zhengzhou University), Xin Li(China Medical University)
Cited by 11
Related Papers
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer
|Cancer Cell|2018|251
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250
Reversing insufficient photothermal therapy-induced tumor relapse and metastasis by regulating cancer-associated fibroblasts
|Nature Communications|2022|247
Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study
|The Lancet Infectious Diseases|2015|231